Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

@article{Elliott1994RandomisedDC,
  title={Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.},
  author={Michael J. Elliott and Ravinder N. Maini and Marc Feldmann and Joachim. R. Kalden and Christian E. Antoni and Josef S Smolen and Burkhard Leeb and Ferdinand C. Breedveld and J D John Macfarlane and Hans Bijl},
  journal={Lancet},
  year={1994},
  volume={344 8930},
  pages={1105-10}
}
Tumour necrosis factor alpha (TNF alpha) is a critical inflammatory mediator in rheumatoid arthritis, and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, we previously observed beneficial responses in patients with active rheumatoid arthritis after open-label administration of a chimeric monoclonal antibody to TNF alpha (cA2). We now report the results of a four-centre, randomised double-blind trial of a single infusion of 1 or 10 mg/kg cA2 compared… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
364 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 364 extracted citations

Similar Papers

Loading similar papers…